TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
TFFPTFF Pharmaceuticals(TFFP) Newsfilter·2024-05-23 19:00

The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models FORT WORTH, Texas, May 23, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented ...